• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Mereo BioPharma Group plc

    5/15/25 10:46:23 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MREO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    MEREO BIOPHARMA GROUP PLC

    (Name of Issuer)


    Ordinary Shares, nominal value 0.003, per ordinary share

    (Title of Class of Securities)


    589492107

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    589492107


    1Names of Reporting Persons

    Rock Springs Capital Management LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    33,421,235.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    33,421,235.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    33,421,235.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.2 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    589492107


    1Names of Reporting Persons

    Rock Springs Capital LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    33,421,235.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    33,421,235.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    33,421,235.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.2 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    589492107


    1Names of Reporting Persons

    Rock Springs Capital Master Fund LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    25,808,055.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    25,808,055.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    25,808,055.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.2 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    589492107


    1Names of Reporting Persons

    Mark Bussard
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    33,421,235.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    33,421,235.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    33,421,235.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.2 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    589492107


    1Names of Reporting Persons

    Kris Jenner
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    33,421,235.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    33,421,235.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    33,421,235.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.2 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    MEREO BIOPHARMA GROUP PLC
    (b)Address of issuer's principal executive offices:

    Fourth Floor, One Cavendish Place, London, W1G 0QF, United Kingdom
    Item 2. 
    (a)Name of person filing:

    This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"): i. Rock Springs Capital Management LP ("RSCM"); ii. Rock Springs Capital LLC ("RSC"); iii. Rock Springs Capital Master Fund LP ("Master Fund"); iv. Mark Bussard; and v. Kris Jenner This Statement relates to the ordinary shares (the "Shares") held directly by the Master Fund, which is a Cayman Island exempted limited partnership, and Four Pines Master Fund LP ("Four Pines"), which is a Cayman Islands exempted limited partnership, and indirectly held by RSCM, a Delaware limited partnership, and RSC, a Delaware limited liability company. RSCM serves as the investment manager to each of the Master Fund and Four Pines. RSC is the general partner of RSCM. Mark Bussard and Kris Jenner each own 50% of the management company.
    (b)Address or principal business office or, if none, residence:

    Rock Springs Capital Management LP, Rock Springs Capital LLC, Rock Springs Capital Master Fund LP; Mark Bussard, and Kris Jenner: 650 South Exeter, Suite 1070 Baltimore, MD 21202
    (c)Citizenship:

    Rock Springs Capital Management LP - Delaware; Rock Springs Capital LLC - Delaware; Rock Springs Capital Master Fund LP - Cayman Islands; Mark Bussard - United States; Kris Jenner - United States
    (d)Title of class of securities:

    Ordinary Shares, nominal value 0.003, per ordinary share
    (e)CUSIP No.:

    589492107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    33,421,235
    (b)Percent of class:

    4.2  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    33,421,235

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    33,421,235 As of March 31, 2025, each of RSMC and RSC may be deemed to be the beneficial owners of 6,684,247 ADRs (translates to 33,421,235 shares). The percent of class is determined by dividing the number of Shares beneficially owned by the Reporting Persons by 795,001,444, as reported on the Issuer's 10-K filed on March 26, 2025.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See disclosure in Items 2 and 4 hereof. Certain funds listed in Item 2(a) are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares covered by this Statement that may be deemed to be beneficially owned by the Reporting Persons.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Please see response to Item 2.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Rock Springs Capital Management LP
     
    Signature:/s/ Mark Bussard
    Name/Title:Mark Bussard - Member
    Date:05/15/2025
     
    Rock Springs Capital LLC
     
    Signature:/s/ Mark Bussard
    Name/Title:Mark Bussard - Member
    Date:05/15/2025
     
    Rock Springs Capital Master Fund LP
     
    Signature:/s/ Mark Bussard
    Name/Title:Mark Bussard - Member
    Date:05/15/2025
     
    Mark Bussard
     
    Signature:/s/ Mark Bussard
    Name/Title:Mark Bussard
    Date:05/15/2025
     
    Kris Jenner
     
    Signature:/s/ Kris Jenner
    Name/Title:Kris Jenner
    Date:05/15/2025
    Exhibit Information

    JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Date: May 15, 2025 Rock Springs Capital Management LP By: Rock Springs Capital LLC, General Partner By: Mark Bussard Name: Mark Bussard Title: Member Rock Springs Capital LLC By: Mark Bussard Name: Mark Bussard Title: Member Rock Springs Capital Master Fund LP By: Rock Springs Capital Management LP, Investment Manager By: Rock Springs Capital LLC, General Partner By: Mark Bussard Name: Mark Bussard Title: Member Mark Bussard By: Mark Bussard Name: Mark Bussard Kris Jenner By: Kris Jenner Name: Kris Jenner

    Get the next $MREO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MREO

    DatePrice TargetRatingAnalyst
    3/27/2025$7.00Overweight
    Analyst
    12/6/2024$7.00Buy
    Jefferies
    6/13/2024$8.00Outperform
    Robert W. Baird
    10/13/2023$4.00Buy
    BTIG Research
    8/12/2022$4.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $MREO
    Financials

    Live finance-specific insights

    See more
    • Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

      Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided recent corporate highlights. "As we close out the first quarter of 2025, we continue to anticipate that this will be an important, milestone-rich year for Mereo. The Phase 3 Orbit study of setrusumab in osteogenesis imperfecta remains on track to read-

      5/13/25 7:30:05 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

      Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 Alvelestat granted Orphan Designation by the European Commission for treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) Cash of $69.8 million as of December 31, 2024, expected to fund operations into 2027 LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the full year ended December 31, 2024, and provided recent corporate highlights. "2024 was a

      3/26/25 7:30:36 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

      LONDON, May 15, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $48.7 million as of March 31, 2024 and continues to expect this to fund its operations into 2026. "2024 is off to an exciting start following the completion of enrollment by our partner Ultragenyx in both the Orbit and Cosmic studies of setrusumab in Osteogenesis Imperfecta (OI) along with the continued advancement of the pre-laun

      5/15/24 4:01:44 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MREO
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Mereo BioPharma Group plc

      SCHEDULE 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

      5/15/25 10:46:23 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Mereo BioPharma Group plc

      SCHEDULE 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

      5/14/25 4:34:46 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Group plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Mereo BioPharma Group plc (0001719714) (Filer)

      5/14/25 4:30:10 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MREO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

      Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided recent corporate highlights. "As we close out the first quarter of 2025, we continue to anticipate that this will be an important, milestone-rich year for Mereo. The Phase 3 Orbit study of setrusumab in osteogenesis imperfecta remains on track to read-

      5/13/25 7:30:05 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

      Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 Alvelestat granted Orphan Designation by the European Commission for treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) Cash of $69.8 million as of December 31, 2024, expected to fund operations into 2027 LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the full year ended December 31, 2024, and provided recent corporate highlights. "2024 was a

      3/26/25 7:30:36 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference

      LONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March 12, 2025, at 8:40 am ET / 1:40 pm GMT. A live audio webcast of the fireside chat can be accessed through the Investors section of the Company's website at www.mereobiopharma.com/investors. An archived replay of the webcast will be available on the Company's website for two weeks following the live event. About Mereo Bi

      3/5/25 7:30:00 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MREO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Yoskowitz Marc J

      4 - Mereo BioPharma Group plc (0001719714) (Issuer)

      2/6/25 4:30:22 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Bender Jeremy

      4 - Mereo BioPharma Group plc (0001719714) (Issuer)

      2/6/25 4:30:14 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Shames Daniel

      4 - Mereo BioPharma Group plc (0001719714) (Issuer)

      2/6/25 4:30:06 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MREO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Analyst initiated coverage on Mereo BioPharma with a new price target

      Analyst initiated coverage of Mereo BioPharma with a rating of Overweight and set a new price target of $7.00

      3/27/25 8:18:53 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Mereo BioPharma with a new price target

      Jefferies initiated coverage of Mereo BioPharma with a rating of Buy and set a new price target of $7.00

      12/6/24 7:56:53 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Mereo BioPharma with a new price target

      Robert W. Baird initiated coverage of Mereo BioPharma with a rating of Outperform and set a new price target of $8.00

      6/13/24 7:11:27 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MREO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mereo BioPharma Group plc

      SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

      11/14/24 4:18:45 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mereo BioPharma Group plc

      SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

      11/14/24 3:30:42 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mereo BioPharma Group plc

      SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

      11/14/24 11:44:32 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MREO
    Leadership Updates

    Live Leadership Updates

    See more
    • Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors

      LONDON and REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Dr. Abdul Mullick to the Company's Board of Directors, effective immediately. Dr. Mullick joins Mereo's Board with over 20 years of experience in the pharmaceutical industry in senior leadership positions across multiple therapeutic areas and geographies, including in rare diseases. "We are very excited to welcome Abdul to the Board at such a pivotal time for the Company," said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo. "His e

      5/17/22 8:00:00 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Announces Appointment of Anne Hyland to Board of Directors

      LONDON and REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Anne Hyland to the Company's Board of Directors, effective immediately. Ms. Hyland has also been appointed to serve on the Audit and Risk Committee of the Board. Ms. Hyland joins Mereo's Board with over 30 years of financial experience in both private and public companies in the biopharmaceutical space. "We are very excited to welcome someone with Anne's level of operational and board experience to our Board," said Dr. Denise Scots-Knight, C

      3/1/22 8:00:00 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Announces Appointment of Pierre Jacquet, M.D., Ph.D. to Board of Directors

      LONDON and REDWOOD CITY, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Pierre Jacquet, M.D., Ph.D to the Company's Board of Directors, effective September 20, 2021. Dr. Jacquet joins Mereo's Board with over two decades of multidisciplinary experience in the life science industry, including corporate strategy, M&A advisory and value management. "We are delighted to have Pierre joining our board of directors at such an exciting and important time for the Company," said Dr. Denise Scots-Knight, Chief Executive Off

      9/20/21 8:00:00 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care